Giant cell arteritis (GCA) is a chronic vasculitis that can lead to permanent vision loss. In this case we describe a patient with permanent monocular vision loss from GCA, managed with long-term glucocorticoids, who presented with elevated erythrocyte sedimentation rate and acute visual loss. This patient was promptly given intravenous steroids, with initial improvement, however, she again experienced acute vision loss on the fourth day of treatment. Given the rare nature of this recurrent GCA-related vision loss during treatment, a broader workup was pursued without an alternative cause identified. Temporal biopsy was not performed due to concern of a false-negative in the setting of chronic steroid use. In this report we discuss the long-term monitoring and management of GCA, recurrence in the acute treatment setting, and present evidence related to diagnosis of GCA in the context of long-term steroid use.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864387PMC
http://dx.doi.org/10.56305/001c.92898DOI Listing

Publication Analysis

Top Keywords

vision loss
20
loss patient
8
giant cell
8
cell arteritis
8
loss
6
recurrent vision
4
patient giant
4
arteritis high
4
high dose
4
dose corticosteroids
4

Similar Publications

Excitatory and inhibitory neurotransmitter alterations with advancing age and injury in the mouse retina.

Neurobiol Aging

March 2025

Neuroscience and Behavioural Diseases and Eye-ACP, SERI/SNEC, Centre for Vision Research, Duke-NUS Medical School, 8 College Road, 169857, Singapore; Save Sight Institute, University of Sydney, Sydney, NSW, Australia. Electronic address:

Increasing age and elevated intraocular pressure (IOP) are the two major risk factors for glaucoma, the most common cause of irreversible blindness worldwide. Accumulating evidence is pointing to metabolic failure predisposing to neuronal loss with advancing age and IOP injury. Many neurotransmitters are synthesized from endogenous metabolites and are essential for correct cell to cell signaling along the visual pathways.

View Article and Find Full Text PDF

Background: Retinitis pigmentosa (RP) is a retinal dystrophy and genetically heterogeneous group that causes vision loss and necessitates innovative therapeutic strategies, and mesenchymal stem cell (MSC) therapy has shown potential due to its regenerative and immunomodulatory properties. This meta-analysis aims to evaluate the efficacy and safety of MSC therapies in improving visual outcomes, focusing on the impact of various MSC types, administration methods, and duration of benefits.

Methods: A systematic search of peer-reviewed studies was conducted to identify clinical trials and observational studies investigating MSC therapies for retinal conditions.

View Article and Find Full Text PDF

Purpose: After stromal injury to the cornea, the release of growth factors and pro-inflammatory cytokines promotes the activation of quiescent keratocytes into a migratory fibroblast and/or fibrotic myofibroblast phenotype. Persistence of the myofibroblast phenotype can lead to corneal fibrosis and scarring, which are leading causes of blindness worldwide. This study aims to establish comprehensive transcriptional profiles for cultured corneal keratocytes, fibroblasts, and myofibroblasts to gain insights into the mechanisms through which these phenotypic changes occur.

View Article and Find Full Text PDF

Research on brain plasticity, particularly in the context of deafness, consistently emphasizes the reorganization of the auditory cortex. But to what extent do all individuals with deafness show the same level of reorganization? To address this question, we examined the individual differences in functional connectivity (FC) from the deprived auditory cortex. Our findings demonstrate remarkable differentiation between individuals deriving from the absence of shared auditory experiences, resulting in heightened FC variability among deaf individuals, compared to more consistent FC in the hearing group.

View Article and Find Full Text PDF

Diabetic Retinopathy (DR): Mechanisms, Current Therapies, and Emerging Strategies.

Cells

March 2025

New Drug Development Center, Daegu-Gyeongbukk Medical Innovation Foundation (K-MEDI hub), 80 Cheombok-ro, Dong-gu, Daegu 41061, Republic of Korea.

Diabetic retinopathy (DR) is one of the most prevalent complications of diabetes, affecting nearly one-third of patients with diabetes mellitus and remaining a leading cause of blindness worldwide. Among the various diabetes-induced complications, DR is of particular importance due to its direct impact on vision and the irreversible damage to the retina. DR is characterized by multiple pathological processes, primarily a hyperglycemia-induced inflammatory response and oxidative stress.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!